Bio-Rad Laboratories has launched its new magnetic bead - based multiplex immunoassays for human T-helper type 17 (Th17) cytokines and cancer biomarkers
The Bio-Plex Pro immunoassays take advantage of the magnetic bead workflow to simplify assay preparation and reduce variability.
The Bio-Plex Pro Human Th17 cytokine panel detects 16 soluble proteins involved in the Th17 immune response pathway.
The Bio-Plex Pro human cancer biomarker panel 1 detects 16 biomarkers commonly associated with cancer.
These assays are designed to help preclinical and clinical researchers investigate mechanisms of disease and therapeutic drug action.
The Bio-Plex Pro Human Th17 cytokine panel features nine new targets, including IL-17F, IL-21, and IL-22, which are commonly requested by researchers, as well as IL-17 A/F, which is unique to Bio-Rad.
The Th17 cytokines are believed to play a key role in inflammatory conditions such as autoimmune diseases, antimicrobial immunity, transplant rejection, and cancer.
The Bio-Plex Pro human cancer biomarker panel 1 incorporates eight new targets including sEGFR, sVEGFR-1, and osteopontin, as well as three targets unique to the Bio-Plex system: sTIE-2, follistatin, and PECAM-1.
These targets are associated with the progression of cancer, including sustained angiogenesis, self-sufficiency in growth signals, and tissue invasion and metastasis.
According to the company, Bio-Plex Pro assays provide many advantages over other xMAP and ELISA offerings, including: Faster assay run time - shorter (one hour) incubation times yield results in three hours compared to other assays, which require overnight incubation; better performance; broader assay working range for increased confidence in sample detection; higher sensitivity (0.1 pg/ml for some assays); and flexible ordering options. The Bio-Plex Pro human Th17 cytokine and human cancer biomarker assays are compatible with all Bio-Plex readers, as well as Luminex 200, FLEXMAP 3D, and MAGPIX instruments.
